CA2565918A1 - Procede et appareil de modelisation predictive en temps reel destines a des patients chroniquement malades - Google Patents
Procede et appareil de modelisation predictive en temps reel destines a des patients chroniquement malades Download PDFInfo
- Publication number
- CA2565918A1 CA2565918A1 CA002565918A CA2565918A CA2565918A1 CA 2565918 A1 CA2565918 A1 CA 2565918A1 CA 002565918 A CA002565918 A CA 002565918A CA 2565918 A CA2565918 A CA 2565918A CA 2565918 A1 CA2565918 A1 CA 2565918A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- data
- time series
- measurements
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 103
- 208000017667 Chronic Disease Diseases 0.000 title claims abstract description 57
- 238000004458 analytical method Methods 0.000 claims abstract description 59
- 239000008280 blood Substances 0.000 claims description 67
- 210000004369 blood Anatomy 0.000 claims description 67
- 238000004422 calculation algorithm Methods 0.000 claims description 65
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 60
- 239000008103 glucose Substances 0.000 claims description 60
- 238000005259 measurement Methods 0.000 claims description 50
- 238000012360 testing method Methods 0.000 claims description 41
- 230000036772 blood pressure Effects 0.000 claims description 32
- 238000001514 detection method Methods 0.000 claims description 26
- 230000037081 physical activity Effects 0.000 claims description 23
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 12
- 238000005295 random walk Methods 0.000 claims description 9
- 238000013459 approach Methods 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 238000013528 artificial neural network Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 238000003909 pattern recognition Methods 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 abstract description 13
- 230000005540 biological transmission Effects 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 6
- 230000003442 weekly effect Effects 0.000 abstract description 6
- 238000013480 data collection Methods 0.000 abstract description 4
- 230000008859 change Effects 0.000 description 47
- 238000009826 distribution Methods 0.000 description 37
- 206010012601 diabetes mellitus Diseases 0.000 description 28
- 235000021152 breakfast Nutrition 0.000 description 26
- 230000008569 process Effects 0.000 description 23
- 230000006870 function Effects 0.000 description 15
- 230000036541 health Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000003205 diastolic effect Effects 0.000 description 11
- 235000001727 glucose Nutrition 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 230000002452 interceptive effect Effects 0.000 description 9
- 238000012549 training Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000013488 ordinary least square regression Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 238000007476 Maximum Likelihood Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000010972 statistical evaluation Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000003121 nonmonotonic effect Effects 0.000 description 3
- 238000010845 search algorithm Methods 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000005315 distribution function Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000005309 stochastic process Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56915104P | 2004-05-07 | 2004-05-07 | |
| US60/569,151 | 2004-05-07 | ||
| US59262304P | 2004-07-30 | 2004-07-30 | |
| US60/592,623 | 2004-07-30 | ||
| US11/074,425 | 2005-03-08 | ||
| US11/074,425 US20060025931A1 (en) | 2004-07-30 | 2005-03-08 | Method and apparatus for real time predictive modeling for chronically ill patients |
| PCT/US2005/015877 WO2005110029A2 (fr) | 2004-05-07 | 2005-05-06 | Procede et appareil de modelisation predictive en temps reel destines a des patients chroniquement malades |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2565918A1 true CA2565918A1 (fr) | 2005-11-24 |
Family
ID=35394594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002565918A Abandoned CA2565918A1 (fr) | 2004-05-07 | 2005-05-06 | Procede et appareil de modelisation predictive en temps reel destines a des patients chroniquement malades |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1810197A4 (fr) |
| JP (1) | JP2007536645A (fr) |
| CA (1) | CA2565918A1 (fr) |
| WO (1) | WO2005110029A2 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007070247A2 (fr) * | 2005-11-29 | 2007-06-21 | Venture Gain, L.L.C. | Monitorage de santé humaine à base de restes |
| US20080235049A1 (en) * | 2007-03-23 | 2008-09-25 | General Electric Company | Method and System for Predictive Modeling of Patient Outcomes |
| JP5219700B2 (ja) * | 2008-09-01 | 2013-06-26 | オムロンヘルスケア株式会社 | 生体指標管理装置 |
| JP5083297B2 (ja) * | 2009-11-18 | 2012-11-28 | セイコーエプソン株式会社 | 予測血糖値算出装置、予測血糖値算出方法およびプログラム |
| US8460220B2 (en) * | 2009-12-18 | 2013-06-11 | General Electric Company | System and method for monitoring the gait characteristics of a group of individuals |
| US20140309511A1 (en) * | 2011-12-06 | 2014-10-16 | Dianovator Ab | Medical arrangements and a method for prediction of a value related to a medical condition |
| KR101710752B1 (ko) * | 2014-06-24 | 2017-02-28 | 경희대학교 산학협력단 | 응급 정신의학적 정신 상태 예측 모델 기반의 응급 원격정신의학 시스템 및 방법 |
| WO2015199258A1 (fr) * | 2014-06-25 | 2015-12-30 | 삼성전자 주식회사 | Système et procédé de génération de modèles de diagnostic |
| US20170032241A1 (en) * | 2015-07-27 | 2017-02-02 | Google Inc. | Analyzing health events using recurrent neural networks |
| US9652712B2 (en) | 2015-07-27 | 2017-05-16 | Google Inc. | Analyzing health events using recurrent neural networks |
| US9336482B1 (en) | 2015-07-27 | 2016-05-10 | Google Inc. | Predicting likelihoods of conditions being satisfied using recurrent neural networks |
| EP3131038A1 (fr) * | 2015-08-14 | 2017-02-15 | Universite De Liege | Dispositif de prédiction |
| US10956821B2 (en) | 2016-11-29 | 2021-03-23 | International Business Machines Corporation | Accurate temporal event predictive modeling |
| GB201817893D0 (en) * | 2018-11-01 | 2018-12-19 | Imperial Innovations Ltd | Predicting physological parameters |
| EP3908175A4 (fr) * | 2019-01-08 | 2022-11-02 | Iluria Ltd. | Diagnostic et efficacité de surveillance d'un trouble d'hyperactivité avec déficit de l'attention |
| CN112971791B (zh) * | 2020-03-23 | 2024-04-05 | 北京海思瑞格科技有限公司 | 一种个体化的生理状态监测分析方法和设备 |
| CN114676176A (zh) * | 2022-03-24 | 2022-06-28 | 腾讯科技（深圳）有限公司 | 时间序列的预测方法、装置、设备及程序产品 |
| CN117409984B (zh) * | 2023-09-21 | 2024-07-02 | 山东第一医科大学附属省立医院 | 一种糖尿病随访管理系统、装置、电子设备和存储介质 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5311876A (en) * | 1992-11-18 | 1994-05-17 | The Johns Hopkins University | Automatic detection of seizures using electroencephalographic signals |
| ATE392178T1 (de) * | 2000-08-18 | 2008-05-15 | Animas Technologies Llc | Vorrichtung zum vorhersagen von hypoglyecemiefällen |
-
2005
- 2005-05-06 EP EP05750636A patent/EP1810197A4/fr not_active Withdrawn
- 2005-05-06 WO PCT/US2005/015877 patent/WO2005110029A2/fr active Application Filing
- 2005-05-06 CA CA002565918A patent/CA2565918A1/fr not_active Abandoned
- 2005-05-06 JP JP2007511641A patent/JP2007536645A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1810197A4 (fr) | 2009-08-05 |
| WO2005110029A2 (fr) | 2005-11-24 |
| WO2005110029A3 (fr) | 2007-05-31 |
| EP1810197A2 (fr) | 2007-07-25 |
| JP2007536645A (ja) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060025931A1 (en) | Method and apparatus for real time predictive modeling for chronically ill patients | |
| CA2565918A1 (fr) | Procede et appareil de modelisation predictive en temps reel destines a des patients chroniquement malades | |
| Sood et al. | IoT-fog-based healthcare framework to identify and control hypertension attack | |
| Lehmann et al. | Application of computers in diabetes carea review. I. Computers for data collection and interpretation | |
| US20200221990A1 (en) | Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation | |
| RU2283495C2 (ru) | Способ, система и программный продукт для оценки контроля гликемии при диабете | |
| CN101278847B (zh) | 高/低血糖、葡萄糖变异性和无效自我监测的系统、方法 | |
| KR102400740B1 (ko) | 사용자의 건강상태 모니터링 시스템 및 이의 분석 방법 | |
| CA2630207A1 (fr) | Systemes, methodes et programmes informatiques pour la surveillance, le diagnostic et le traitement a distance d'etats pathologiques presentes par des patients | |
| Sandham et al. | Blood glucose prediction for diabetes therapy using a recurrent artificial neural network | |
| CN100466965C (zh) | 用于处理自我监测血糖(smbg)数据从而提高糖尿病患者自我管理的方法、系统和计算机程序产品 | |
| Hernando et al. | DIABNET: a qualitative model-based advisory system for therapy planning in gestational diabetes | |
| US8428965B2 (en) | System for clinical research and clinical management of cardiovascular risk using ambulatory blood pressure monitoring and actigraphy | |
| Kalatzis et al. | Interactive dimensionality reduction for improving patient adherence in remote health monitoring | |
| US20030018240A1 (en) | Chronic heart failure patient identification system | |
| KR20030070871A (ko) | 인터넷을 기반으로 한 종합 건강관리 및 정보제공 방법 | |
| Alhorishi et al. | Using machine learning to predict early preparation of pharmacy prescriptions at psmmc-a comparison of four machine learning algorithms | |
| Cramp et al. | Assessing health policy strategies: A model-based approach to decision support | |
| Rathi et al. | Assessing mental health crisis in pandemic situation with computational intelligence | |
| CN117112729B (zh) | 基于人工智能的医疗资源对接方法及系统 | |
| KR102382659B1 (ko) | 당화혈색소 수치 추정을 위한 인공지능학습 모델의 학습 방법 및 그 시스템 | |
| US20220375617A1 (en) | Computerized decision support tool for preventing falls in post-acute care patients | |
| Vardhan et al. | Study on Diabetes Management using METABO on ICT | |
| Muhammad et al. | Research Article An ML-Enabled Internet of Things Framework for Early Detection of Heart Disease | |
| Egejuru et al. | An Online Hypertension Risk Monitoring System |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |